Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)

Next Previous
Trial Profile

A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Acronyms ATTUNE
  • Sponsors Bionomics

Most Recent Events

  • 27 May 2025 According to the Neuphoria Therapeutics media release, company announced an upcoming presentation of this data from this study at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting.
  • 09 Dec 2024 According to a Bionomics media release, positive results from this study have been published in the NEJM Evidence. and also presented at the 63th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) as part of the inaugural "Promising Targets" session.
  • 03 Dec 2024 According to a Bionomics media release, company announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial at the 63th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) being held December 8-11, 2024 in Phoenix, AZ.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top